Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Novelli, Silvana
  • Bento, Leyre
  • Garcia, Irene
  • Prieto, Laura
  • Lopez, Lucia
  • Gutierrez, Gonzalo
  • Hernani, Rafael
  • Perez, Ariadna
  • Esquirol, Albert
  • Solano, Carlos
  • Bastos, Mariana
  • Dorado, Nieves
  • Rodriguez, Nancy
  • Rodriguez, Guillermo
  • Herrera, Pilar
  • Luna, Alejandro
  • Parody, Rocio
  • Martin, Carmen
  • Garcia, Estefania
  • Lopez, Oriana
  • Heras, Inmaculada
  • Zanabili, Joud
  • Moraleda, Jose M
  • Yanez, Lucrecia
  • Gutierrez, Antonio
  • Zudaire, Teresa
  • Cordoba, Raul
  • Varela, Rosario
  • Ferra, Christelle
  • Martinez, Joaquin
  • Martinez, Carmen
  • Gonzalez-Barca, Eva
  • Martino, Rodrigo
  • Caballero, Dolores

Grupos

Abstract

Despite advances in understanding the biology of mature T and natural killer (NK)/T cell neoplasia, current therapies, even the most innovative ones, are still far from ensuring its cure. The only treatment to date that has been shown to control aggressive T cell neoplasms in the long term is allogeneic stem cell transplantation (alloSCT). We aim to report the results of alloSCT for advanced mature T and NK/T neoplasias performed in centers from our national GELTAMO/GETH (Grupo Espanol de Linfoma y Trasplante de Medula Osea/Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular) over the past 25 years. As a secondary objective, we analyzed the results of alloSCT from haploidentical donors. We performed a retrospective analysis of all patients who received an alloSCT in Spanish centers (n = 201) from September 1995 to August 2018. The 2-year overall survival (OS) and disease-free survival (DFS) were 65.5% and 58.2%, respectively. The univariate for OS and DFS showed statistically different hazard ratios for conditioning intensity, response pre-alloSCT, comorbidity index, donor/receptor cytomegalovirus status and Eastern Cooperative Oncology Group (ECOG) pre-alloSCT, but only a better ECOG pre-alloSCT remained significant in the multivariate analysis. There was an increased incidence of relapse in those patients who did not develop chronic graft-versus-host disease (GVHD) and an increased risk of death in those developing moderate to severe acute GVHD. The 1-year nonrelapse mortality was 21.9% and was mainly due to GVHD (30%) and bacterial infections (17%). When comparing unrelated donors with haploidentical donors, we found similar results in terms of OS and DFS. There was, however, a reduction of acute GVHD in the haploidentical group (P = .04) and trend to a reduction of chronic GVHD. In conclusion, alloSCT is the only curative option for most aggressive T cell neoplasias. Haploidentical donors offer similar results to related donors in terms of survival with a reduction of acute GVHD. (C) 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
2666-6375, 2666-6367

Transplantation and Cellular Therapy  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
4931-4938
PubMed:
33857447

Citas Recibidas en Web of Science: 9

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Allogeneic stem cell transplantation; Haploidentical; T cell lymphoma

Campos de Estudio

Cita

Compartir